Inhibitor Bea428

Inhibitor Bea428 is an experimental small molecule inhibitor designed to target the HIV‑1 protease enzyme. It belongs to the class of organic compounds known as n-acyl-alpha amino acids and derivatives. Structurally characterized by two central hydroxy groups that mimic the geminal hydroxy groups of a cleavage-reaction intermediate in HIV‑1 protease substrates, it binds within the active site of HIV‑1 protease and inhibits its enzymatic activity. This mechanism disrupts viral polyprotein processing essential for maturation and infectivity of HIV particles. The compound has been studied primarily in structural biology contexts to understand binding interactions with wild-type and mutant forms of HIV‑1 protease; it is not approved for clinical use or marketed as a therapeutic agent[1][2][3][4].

Other names

INHIBITOR BEA428(2R,3R,4R,5R)-3,4-dihydroxy-N,N'-bis((1S)-2-methyl-1-(methyl-C-hydroxycarbonimidoyl)propyl)-2,5-bis(((4-(pyridin-3-yl)phenyl)methoxy))hexanediimidic acidN,N-[2,5-O-[DI-4-PYRIDIN-3-YL-BENZYL]-GLUCARYL]-DI-[VALYL-AMIDO-METHANE]N1,N6-bis[(1S)-2-Methyl-1-(methylcarbamoyl)propyl]-(2R,3R,4R,5R)-2,5-bis[4-(3-pyridyl)benzyloxy]-3,4-dihydroxyhexanediamide